full list rate price target
earn chang report pleas see
tabl page
back school outlook
challeng start sector momentum increas fall although us
biopharma start distinctli neg note momentum gradual shift
year sentiment decidedli posit head fall continu trend
observ prior earn exit august remain well broader
market ytd nbi vs pharma still lag despit
close gap somewhat drg turnaround
attribut typic season strength littl sign inventori issu
previous weigh number name clinic regulatori valid
innov platformsinclud rnai/silenc differ cell gene therapi
approacheshav help re-engag hc specialist continu believ
meaning large-scal activ high-profil phase data like requir
recaptur signific generalist interest especi pharma continu
posit bia sector head given expect
momentum despit uncertainti regard impact extent potenti
healthcar reform discuss current state healthcarealong issu
like impact sector fallw host call today
et slide dial-in us passcod
 biotech deal multipl reach new rel high ytd number
 deal pace match total deal volum
alreadi outpac last two year like
underscor retic larg cap one manag recent describ
market frothi ytd transact multipl averag median
highest valu last sever year vs second highest averag
merck well-posit among larg cap among large-cap biopharma continu
see upsid merck given domin i/o posit follow recent fda
approv nsclc base remain confid increas
keytruda penetr rais pt addit
expect read-out tnbc chl
posit drive upsid also increas pt
continu sign strength differenti diabet portfolio
ahead rewind cv outcom studi expect later year
neurocrin continu impress among smaller cap ingrezza remain one
impress recent launch biotech despit mani consid
challeng patient popul favor oper trend like drive
penetr ahead pediatr tourett syndrom data expect year end
along addit potenti near-term upsid orilissa endometriosi
potenti uterin fibroid opicapon parkinson ahead
catalyst continu see unlock valu share
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
valuat methodolog risk
valuat methodolog price target reflect blend averag price earn multipl analysi assum current
year multipl sustain forward year earn impli per share dcf also impli intrins valu per
risk may imped achiev barclay research valuat price intermediate-term outlook depend
larg commerci execut success launch new diabet immunolog oncolog asset market highli
competit adopt may strong forecast addit pipelin failur high risk high reward pipelin asset may
leav earli intermedi stage asset drive futur growth
valuat methodolog price target reflect blend averag price-to-earnings multipl analysi assum merck share hold
forward year price-to-earnings multipl ep impli valu approxim dcf analysi assum
wacc termin growth suggest intrins valu approxim
risk may imped achiev barclay research valuat price downsid risk includ slower commerci
uptak keytruda price pressur neg affect januvia growth slow growth remaind portfolio neg clinic
trial outcom limit keytruda label expans
overweight exit yz period
new commerci stage portfolio attract diabet
oncolog immunolog asset model
forecast mid single-digit sale low double-digit
ep growth major
pharma averag execut product
cadenc think current multipl
faster expect commerci launch
expect jardianc trulic taltz
baricitinib could drive upsid potenti
re-rat biotech-lik multipl
slow uptak new diabet immunolog
margin pressur early/intermedi pipelin
failur could caus concern long term
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ merck like
continu take share lung back
posit data addit
view perhap first-lin lung
market share grab us support
ow rate
faster uptak keytruda nsclc i/o
combin data acceler develop
preserv market share de-risk pipelin
posit pipelin data could put upward bia
consensu estim re-rat stock
continu weak core brand like remicad
januvia coupl faster share declin
keytruda pipelin setback could depress
revenu estim forward multipl
like drive upsid next
month view elagolix peak
potenti base data endometriosi uterin
fibroid ingrezza posit tourett data
stronger expect launch td could provid
better-than-expect launch ingrezza tardiv
dyskinesia orilissa endometriosi along
approv launch uterin fibroid posit
clinic data ingrezza tourett
acceler path fda approv
opicapon parkinson
ingrezza clinic effect tourett meaning
launch ingrezza td begin slow/declin
delay filing/ approval/ uptak orilissa
margin return data
balanc sheet cash flow
equival mn
short long-term debt
chang work capit
flow oper mn
valuat leverag metric
eli lilli price target reflect blend averag price earn
multipl analysi assum current year multipl sustain forward year
earn impli per share dcf also impli
intrins valu per share
merck price target reflect blend averag price-to-earnings multipl
analysi assum merck share hold forward year price-to-earnings
multipl ep impli valu approxim
dcf analysi assum wacc termin growth
suggest intrins valu approxim share
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
